

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/Caplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/Caplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/Caplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/Caplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/Caplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/Caplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/Caplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/Caplus patent kind codes will be updated
NEWS 25	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS EXPRESS	NOVEMBER 10	CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:38:45 ON 06 DEC 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:39:01 ON 06 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

DICTIONARY FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TS&A INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10824037.str



```

chain nodes :
15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
1-15 4-9
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :
1-2 1-6 1-15 2-3 3-4 4-5 5-6
exact bonds :
3-8 4-9 5-7 7-8
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

```

G1:C,H

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:39:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 720 TO 1640
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:39:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1318 TO ITERATE

100.0% PROCESSED 1318 ITERATIONS 204 ANSWERS
SEARCH TIME: 00.00.01

L3 204 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 09:39:38 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 5 Dec 2006 (20061205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 12 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1176029 CAPLUS

TITLE: Preparation of benzotriazinones and phenoxazines as α 1 adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia

INVENTOR(S): Sarma, Pakala Kumara Savithru; Sharma, Somesh; Dharmarajan, Sankaranarayanan; Shelke, Sandeep Y.; Pal, Arani; Kondaskar, Atul; Gupta, Praful; Chugh, Anita; Tiwari, Atul; Nanda, Kamna

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117760	A1	20061109	WO 2006-IB51392	20060503
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			IN 2005-DE1099	A 20050503
GI				



II

AB Compds. R1-A-X1R2R3 [I, wherein X1 = N or CR4; R4 = H, OH or alkyl; A = aryl, aryloxy, alkyl, etc.; R1 - R3 = H, halo, alkyl, etc.; R2 and R3 together with X1 to which they are attached also form a ring] and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides or metabolites thereof were prepared as α 1 adrenergic receptor antagonists. A number of benzotriazinones and phenoxazines were disclosed as examples. For instance, N-alkylation of 1,2,3-benzotriazin-4(3H)-one with 1,3-dibromopropane followed by amination of the resulting bromide with 4-(2-methoxyphenyl)piperidin-4-ol gave II, which was converted into its salt by treatment with HCl. The invented compds. showed inhibition against α 1a and α 1b adrenergic receptors with Ki values of 0.5-2500 nM and 5-1333 nM, resp. Therefore, I can be used to treat diseases mediated through α 1a and/or α 1b adrenergic receptors such as benign prostatic hyperplasia (BPH) and related symptoms thereof.


IT 914290-23-6P 914290-45-2P 914290-82-7P
914291-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzotriazinones and phenoxazines as α 1 adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia)

RN 914290-23-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● x HCl


RN 914290-45-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




● x HCl


RN 914290-82-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 914291-00-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 914289-94-4P 914289-95-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzotriazinones and phenoxazines as $\alpha 1$ adrenergic
receptor antagonists for the treatment of benign prostatic hyperplasia)
RN 914289-94-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 914289-95-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:162035 CAPLUS

DOCUMENT NUMBER: 142:233377

TITLE: Pharmaceutical composition and method using a
combination of an opioid receptor antagonist and an
 $\alpha 2\delta$ ligand for the prevention and
treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy,
Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043345	A1	20050224	US 2004-870821	20040617
CA 2535814	AA	20050303	CA 2004-2535814	20040809
WO 2005018670	A1	20050303	WO 2004-IB2602	20040809
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1658098	A1	20060524	EP 2004-744237	20040809
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004013608	A	20061017	BR 2004-13608	20040809
PRIORITY APPLN. INFO.:			US 2003-497372P	P 20030822
			WO 2004-IB2602	W 20040809

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and an $\alpha 2\delta$ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT 778582-19-7 778582-23-3 778582-27-7


778582-32-4 778582-34-6 778582-60-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(opioid receptor antagonist- $\alpha 2\delta$ ligand combination for
prevention and treatment of addiction)


RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-
azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-
azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-27-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-
methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-32-4 CAPLUS


CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-
methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX
NAME)



RN 778582-34-6 CAPLUS


CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS

CN Benzamide, 3-[[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160837 CAPLUS

DOCUMENT NUMBER: 142:233372

TITLE: Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043327	A1	20050224	US 2004-870209	20040617
CA 2536280	AA	20050303	CA 2004-2536280	20040809
WO 2005018645	A1	20050303	WO 2004-IB2596	20040809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658082	A1	20060524	EP 2004-744231	20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

BR 2004013693
PRIORITY APPLN. INFO.:

A 20061024

BR 2004-13693
US 2003-496803P
WO 2004-IB2596

20040809
P 20030821
W 20040809

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.


IT 778582-19-7 778582-23-3 778582-27-7
778582-32-4 778582-34-6 778582-60-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)


RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-27-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-32-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-34-6 CAPLUS

CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS

CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:995777 CAPLUS

DOCUMENT NUMBER: 141:406121

TITLE: New pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms
INVENTOR(S): Saltarelli, Mario David; Lowe, John Adams

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 59 pp., Division of U.S. Ser. No. 572,619.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229911	A1	20041118	US 2004-867123	20040614
PRIORITY APPLN. INFO.:			US 2000-572619	A3 20000517
OTHER SOURCE(S):	MARPAT 141:406121			

AB The present invention relates to new pharmaceutical uses for compds. that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically,

it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI (selective serotonin reuptake inhibitor) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.


IT 208837-35-8 310433-73-9 310433-74-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms)


RN 208837-35-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 310433-73-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 310433-74-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN



ACCESSION NUMBER: 2004:872783 CAPLUS

DOCUMENT NUMBER: 141:366141

TITLE: Preparation of 3-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as opioid

receptor modulators
 INVENTOR(S): Coe, Jotham Wadsworth; Mchardy, Stanton Furst;
 Bashore, Crystal Gayle
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089908	A2	20041021	WO 2004-IB1189	20040402
WO 2004089908	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522323	AA	20041021	CA 2004-2522323	20040402
EP 1615894	A2	20060118	EP 2004-725450	20040402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009307	A	20060425	BR 2004-9307	20040402
JP 2006522795	T2	20061005	JP 2006-506489	20040402
NL 1025932	A1	20041018	NL 2004-1025932	20040413
NL 1025932	C2	20051122		
US 2004259859	A1	20041223	US 2004-824037	20040414
PRIORITY APPLN. INFO.:			US 2003-462629P	P 20030414
			WO 2004-IB1189	W 20040402
OTHER SOURCE(S):	MARPAT 141:366141			
GI				



AB 3-Azabicyclo[3.2.1]octanes, such as I [R = H, OH, CN, NH₂, CONH₂, alkyl, alkynyl, alkylsulfonylamino, etc.; R₃ = alkyl, arylalkyl, heteroarylalkyl, etc.; R₈ = H, OH, OMe] and specifically II, were prepared for therapeutic use in the treatment of disease states, disorders and conditions mediated by opioid receptors, such as irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders.

IT 778582-18-6P 778582-19-7P 778582-20-0P
 778582-21-1P 778582-22-2P 778582-23-3P
 778582-24-4P 778582-25-5P 778582-26-6P


778582-27-7P 778582-28-8P 778582-29-9P
 778582-30-2P 778582-31-3P 778582-32-4P
 778582-33-5P 778582-34-6P 778582-35-7P
 778582-36-8P 778582-37-9P 778582-38-0P
 778582-39-1P 778582-40-4P 778582-41-5P
 778582-42-6P 778582-43-7P 778582-44-8P
 778582-45-9P 778582-46-0P 778582-47-1P
 778582-48-2P 778582-49-3P 778582-50-6P
 778582-51-7P 778582-52-8P 778582-53-9P
 778582-54-0P 778582-55-1P 778582-56-2P
 778582-57-3P 778582-58-4P 778582-59-5P
 778582-60-8P 778582-61-9P 778582-62-0P
 778582-63-1P 778582-64-2P 778582-65-3P
 778582-66-4P 778582-67-5P 778582-68-6P
 778582-69-7P 778582-70-0P 778582-71-1P
 778582-72-2P 778582-73-3P 778582-74-4P
 778582-75-5P 778582-76-6P 778582-77-7P
 778582-78-8P 778582-79-9P 778582-80-2P
 778582-81-3P 778582-82-4P 778582-83-5P
 778582-84-6P 778582-85-7P 778582-86-8P
 778582-87-9P 778582-88-0P 778582-89-1P
 778582-90-4P 778582-91-5P 778582-92-6P
 778582-93-7P 778582-94-8P 778582-95-9P
 778582-96-0P 778582-97-1P 778582-98-2P
 778582-99-3P 778583-01-0P 778583-05-4P
 778583-07-6P 778583-09-8P 778583-11-2P
 778583-12-3P 778583-14-5P 778583-17-8P
 778583-18-9P 778583-19-0P 778583-20-3P
 778583-21-4P 778583-22-5P 778583-23-6P
 778583-24-7P 778583-25-8P 778583-26-9P
 778583-27-0P 778583-28-1P 778583-29-2P
 778583-30-5P 778583-31-6P 778583-32-7P
 778583-33-8P 778583-34-9P 778583-35-0P
 778583-36-1P 778583-37-2P 778583-38-3P
 778583-39-4P 778583-40-7P 778583-41-8P
 778583-42-9P 778583-43-0P 778583-44-1P
 778583-45-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical
 compns. as opioid receptor modulators)


RN 778582-18-6 CAPLUS

CN Phenol, 3-[3-(cyclopropylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA
 INDEX NAME)




RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-
 azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-20-0 CAPLUS

CN Phenol, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-21-1 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-22-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-23-3 CAPLUS


CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-24-4 CAPLUS
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[3-(1-hydroxycyclohexyl)propyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778582-25-5 CAPLUS
 CN Benzamide, 3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-26-6 CAPLUS
 CN 1H-Inden-2-ol, 2,3-dihydro-2-[[8-(3-hydroxyphenyl)-3-azabicyclo[3.2.1]oct-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 778582-27-7 CAPLUS
 CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-28-8 CAPLUS
 CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-29-9 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-2-[[8-(3-hydroxyphenyl)-8-methoxy-3-azabicyclo[3.2.1]oct-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 778582-30-2 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-31-3 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-32-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-33-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778582-34-6 CAPLUS

CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-35-7 CAPLUS

CN Ethanone, 1-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 778582-36-8 CAPLUS

CN Benzamide, 3-(3-ethyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-37-9 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-38-0 CAPLUS

CN Benzamide, 3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-39-1 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(1H-pyrrol-2-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-40-4 CAPLUS

CN Benzamide, 3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-41-5 CAPLUS

CN Benzamide, 3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]-
(9CI) (CA INDEX NAME)




RN 778582-42-6 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-pyrrol-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]-
(9CI) (CA INDEX NAME)




RN 778582-43-7 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-
(9CI) (CA INDEX NAME)




RN 778582-44-8 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-
(9CI) (CA INDEX NAME)




RN 778582-45-9 CAPLUS

CN Benzamide, 3-[(8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-46-0 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-47-1 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-48-2 CAPLUS

CN Benzamide, 3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-49-3 CAPLUS

CN Benzamide, 3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-50-6 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-51-7 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-52-8 CAPLUS

CN Benzamide, 3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-53-9 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-54-0 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-55-1 CAPLUS

CN Ethanesulfonamide, N-[3-(8-hydroxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-56-2 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-57-3 CAPLUS

CN Benzamide, 3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-58-4 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-59-5 CAPLUS


CN Benzamide, 3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS


CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-61-9 CAPLUS

CN Ethanesulfonamide, N-[3-(3-hexyl-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-62-0 CAPLUS

CN Benzamide, 3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-63-1 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-64-2 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-65-3 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-66-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-(cyclohexylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-67-5 CAPLUS

CN Benzamide, 3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-68-6 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-69-7 CAPLUS

CN Benzamide, 3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-70-0 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-71-1 CAPLUS

CN Ethanesulfonamide, N-[3-(8-hydroxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-72-2 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-73-3 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-74-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-75-5 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1H-indol-3-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-76-6 CAPLUS

CN Ethanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-77-7 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-78-8 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-79-9 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-80-2 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)

azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-81-3 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-82-4 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-83-5 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(4-hydroxy-1-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-84-6 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-85-7 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-86-8 CAPLUS

CN Ethanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-87-9 CAPLUS

CN Ethanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-88-0 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-89-1 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-90-4 CAPLUS

CN Methanesulfonamide, N-[3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-91-5 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-92-6 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-methylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-93-7 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-94-8 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-95-9 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-96-0 CAPLUS


CN Methanesulfonamide, N-[3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778582-97-1 CAPLUS


CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)

azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-98-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-99-3 CAPLUS

CN Methanesulfonamide, N-[3-(3-heptyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778583-01-0 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-05-4 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-07-6 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-ethylhexyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-09-8 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778583-11-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-12-3 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-14-5 CAPLUS

CN Methanesulfonamide, N-[3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-17-8 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-18-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-19-0 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-20-3 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-21-4 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-22-5 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-23-6 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-24-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-25-8 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-26-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-27-0 CAPLUS

CN Methanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-28-1 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-29-2 CAPLUS

CN Methanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-30-5 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-31-6 CAPLUS

CN Methanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-32-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(3-cyclohexylpropyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778583-33-8 CAPLUS

CN Phenol, 3-[3-(3-cyclohexylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-34-9 CAPLUS

CN Benzamide, 3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-35-0 CAPLUS

CN Benzamide, 3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-36-1 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-37-2 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-38-3 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-39-4 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-40-7 CAPLUS

CN Acetamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 778583-41-8 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-42-9 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 778583-43-0 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 778583-44-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(cyclopropylmethyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 778583-45-2 CAPLUS

CN Phenol, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




IT 778581-99-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as opioid receptor modulators)

RN 778581-99-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT 778581-81-0P 778581-83-2P 778581-84-3P

778581-85-4P 778581-86-5P 778581-87-6P

778581-88-7P 778581-89-8P 778581-90-1P

778581-91-2P 778581-92-3P 778581-93-4P

778581-94-5P 778581-95-6P 778581-96-7P

778581-97-8P 778581-98-9P 778582-00-6P

778582-01-7P 778582-02-8P 778582-03-9P

778582-04-0P 778582-05-1P 778582-06-2P

778582-07-3P 778582-08-4P 778582-09-5P

778582-10-8P 778582-11-9P 778582-12-0P

778582-13-1P 778582-14-2P 778582-15-3P


778582-16-4P 778582-17-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as opioid receptor modulators)


RN 778581-81-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 778581-83-2 CAPLUS


CN 3-Azabicyclo[3.2.1]octane, 8-chloro-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 778581-84-3 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]-
 (9CI) (CA INDEX NAME)




RN 778581-85-4 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 778581-86-5 CAPLUS
 CN Phenol, 3-(3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778581-87-6 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(3-hydroxyphenyl)-,
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 778581-88-7 CAPLUS
 CN Phenol, 3-(3-azabicyclo[3.2.1]oct-8-yl)-, hydrochloride (9CI) (CA INDEX
 NAME)




● HCl


RN 778581-89-8 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[3-
 [(trifluoromethyl)sulfonyl]oxy]phenyl]-, phenylmethyl ester (9CI) (CA
 INDEX NAME)




RN 778581-90-1 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(3-aminophenyl)-,
 phenylmethyl ester (9CI) (CA INDEX NAME)



RN 778581-91-2 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[3-
 [(methylsulfonyl)amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 778581-92-3 CAPLUS
 CN Methanesulfonamide, N-[3-(3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA
 INDEX NAME)




RN 778581-93-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-bromophenyl)-3-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 778581-94-5 CAPLUS

CN Boronic acid, [3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778581-95-6 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-hydroxyphenyl)-3-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 778581-96-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778581-97-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 778581-98-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-00-6 CAPLUS

CN Methanesulfonamide, N-[3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-01-7 CAPLUS

CN Benzonitrile, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-02-8 CAPLUS


CN Benzamide, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-03-9 CAPLUS
 CN Benamide, 3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-04-0 CAPLUS
 CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-05-1 CAPLUS
 CN Ethanesulfonamide, N-[3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-06-2 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-bromophenyl)-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 778582-07-3 CAPLUS
 CN Boronic acid, [3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-08-4 CAPLUS

CN Phenol, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI)
(CA INDEX NAME)




RN 778582-09-5 CAPLUS

CN Phenol, 3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-10-8 CAPLUS

CN Benzenamine, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-
(9CI) (CA INDEX NAME)




RN 778582-11-9 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-12-0 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-
(9CI) (CA INDEX NAME)




RN 778582-13-1 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-14-2 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-15-3 CAPLUS

CN Benzonitrile, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-16-4 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-17-5 CAPLUS

CN Benzamide, 3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:207617 CAPLUS

DOCUMENT NUMBER: 138:369039

TITLE: Synthesis and pharmacology of site specific cocaine abuse treatment agents: 8-substituted isotropane (3-azabicyclo[3.2.1]octane) dopamine uptake inhibitors

AUTHOR(S): Kim, Deog-Il; Schweri, Margaret M.; Deutsch, Howard M.
CORPORATE SOURCE: Georgia Institute of Technology, School of Chemistry and Biochemistry, Atlanta, GA, 30332-0400, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(8), 1456-1464

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 138:369039

GI




- AB A series of 8-substituted-3-azabicyclo[3.2.1]octanes (isotropanes) were synthesized and tested for inhibitor potency using [^3H]WIN 35,428 binding at the dopamine (DA) transporter, [^3H]citalopram binding at the serotonin (5-HT) transporter, and [^3H]DA uptake assays. The synthesis started with a Mannich condensation of cyclopentanone, benzylamine, and formaldehyde to afford N-benzyl-3-azabicyclo[3.2.1]octan-8-one (I). The 8-Ph group was introduced by Grignard addition to ketone I or nucleophilic displacement via a triflate of the corresponding alc. The 8 β -phenyl-8 α -alcs. from Grignard addition generally have low affinity for the two transporters and do not effectively inhibit the uptake of [^3H]DA. The 8 β -Ph compound (II) without the hydroxyl group at C-8 was much more potent (22-fold) for [^3H]WIN 35,428 binding inhibition than the corresponding 8 β -phenyl-8 α -hydroxy compound. The 8 α -Ph compound was almost as potent as cocaine in binding to the DA transporter (IC_{50} = 234 nM vs 159 nM for cocaine); whereas the C-8 epimer was somewhat less potent (IC_{50} = 785 nM). The lower potency of II (β -orientation of 8-Ph group) as compared to II (α -orientation) was unexpected, based on modeling studies comparing the new compds. to WIN 35,065-2, an analog of cocaine. The benzhydryl ethers at C-8 (III), analogous to the benztropines, had better selectivity than the corresponding Ph compds. for the DA transporter as compared to the 5-HT transporter. The isotropane and benzisotropine analogs seem to bind in a manner that is more similar to that of the benztropine compds. rather than those of cocaine and WIN 35,065-2.
- IT 521944-10-5P 521944-11-6P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine analogs and evaluation of their activity as dopamine uptake inhibitors for the potential treatment of cocaine abuse)
- RN 521944-10-5 CAPLUS
- CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-3-(phenylmethyl)-, (8-syn)- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 521944-11-6 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 521944-12-7P 521944-14-9P 521944-19-4P
 521944-20-7P 521944-21-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine analogs and evaluation of their activity as dopamine uptake inhibitors for the potential treatment of cocaine abuse)
 RN 521944-12-7 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 521944-14-9 CAPLUS
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 521944-19-4 CAPLUS
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(4-chlorophenyl)-3-(phenylmethyl)-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-20-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-(phenylmethyl)-, (8-syn)-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-21-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-, (8-syn)- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



IT 15466-28-1P 521944-13-8P 521944-22-9P
521944-23-0P 521944-24-1P 521944-25-2P
521944-26-3P 521944-27-4P 521944-28-5P
521944-29-6P 521944-30-9P 521944-31-0P
521944-32-1P 522608-85-1P 522608-88-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)

(preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine
analogs and evaluation of their activity as dopamine uptake inhibitors
for the potential treatment of cocaine abuse)

RN 15466-28-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 521944-13-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-22-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-methyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-23-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-3-(phenylmethyl)-, hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-24-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(4-chlorophenyl)-3-(phenylmethyl)-, hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-25-2 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, hydrochloride,
 (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-26-3 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-(phenylmethyl)-,
 hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-27-4 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-, hydrochloride, (8-syn)- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-28-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-, hydrochloride, (8-syn)-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-29-6 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8-phenyl-, hydrochloride, (8-syn)-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-30-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-methyl-, hydrochloride,
(8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-31-0 CAPLUS
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-, hydrochloride, (8-syn)- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-32-1 CAPLUS
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, hydrochloride, (8-syn)-
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 522608-85-1 CAPLUS
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, (8-anti)- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 522608-88-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, hydrochloride,
(8-anti)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:841966 CAPLUS
DOCUMENT NUMBER: 134:13350
TITLE: Nitric oxide synthase (NOS) inhibitor combinations
with other agents for treatment of disorders treatable
by altering circadian rhythm
INVENTOR(S): Saltarelli, Mario David; Lowe, John Adams, III
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071107	A2	20001130	WO 2000-IB295	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2374668	AA	20001130	CA 2000-2374668	20000316
EP 1178784	A1	20020213	EP 2000-907891	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010820	A	20020305	BR 2000-10820	20000316
TR 200103351	T2	20020621	TR 2001-3351	20000316
EE 200100611	A	20030217	EE 2001-611	20000316
JP 2003523941	T2	20030812	JP 2000-619414	20000316
HU 200301287	A2	20030828	HU 2003-1287	20000316
CN 1617743	A	20050518	CN 2000-807878	20000316
NO 2001005651	A	20020118	NO 2001-5651	20011120
HR 2001000862	A1	20030630	HR 2001-862	20011120
ZA 2001009555	A	20040407	ZA 2001-9555	20011120
BG 106208	A	20020930	BG 2001-106208	20011211
PRIORITY APPLN. INFO.:			US 1999-135520P	P 19990521

AB New pharmaceutical uses are provided for compds. that exhibit activity as NOS inhibitors. Specifically, the invention provides the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either a selective serotonin reuptake inhibitor (SSRI) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.


IT 208837-35-8 310433-73-9 310433-74-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide synthase inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm)


RN 208837-35-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 310433-73-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 310433-74-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:394325 CAPLUS

DOCUMENT NUMBER: 129:67702


TITLE: Preparation of 6-phenylpyridyl-2-amines as NOS inhibitors
 INVENTOR(S): Lowe, John Adams III
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Lowe, John Adams III
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824766	A1	19980611	WO 1997-IB1446	19971117
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2273479	AA	19980611	CA 1997-2273479	19971117
CA 2273479	C	20060207		
AU 9747917	A1	19980629	AU 1997-47917	19971117
EP 946512	A1	19991006	EP 1997-910587	19971117
EP 946512	B1	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1239952	A	19991229	CN 1997-180350	19971117
CN 1117077	B	20030806		
BR 9714381	A	20000502	BR 1997-14381	19971117
JP 2000505814	T2	20000516	JP 1998-525397	19971117
JP 3604399	B2	20041222		
NZ 335733	A	20010126	NZ 1997-335733	19971117
HU 200001848	A2	20010428	HU 2000-1848	19971117
AT 251612	E	20031015	AT 1997-910587	19971117
PT 946512	T	20040130	PT 1997-910587	19971117
ES 2206691	T3	20040516	ES 1997-910587	19971117
CZ 293863	B6	20040818	CZ 1999-2017	19971117
TW 491840	B	20020621	TW 1997-86117501	19971122
ZA 9710906	A	19990609	ZA 1997-10906	19971204
AP 848	A	20000609	AP 1997-1156	19971204
W: BW, GM, KE, UG, ZM, ZW				
US 6235750	B1	20010522	US 1999-325480	19990603
NO 9902725	A	19990604	NO 1999-2725	19990604
NO 313517	B1	20021014		
KR 2000057413	A	20000915	KR 1999-704981	19990604
BG 103540	A	20001229	BG 1999-103540	19990630
US 6333186	B1	20011225	US 2000-478479	20000106
US 2002032191	A1	20020314	US 2001-802086	20010308
AU 2001072050	A5	20011115	AU 2001-72050	20010913
AU 766080	B2	20031009		
US 2002103227	A1	20020801	US 2001-965564	20010927
US 2002106642	A1	20020808	US 2001-965594	20010927
US 6800456	B2	20041005		
US 2004142924	A1	20040722	US 2003-678369	20031003
JP 2005170924	A2	20050630	JP 2004-186311	20040624
PRIORITY APPLN. INFO.:			US 1996-32793P	P 19961206
			AU 1997-47917	A3 19971117
			JP 1998-525397	A3 19971117
			WO 1997-IB1446	W 19971117
			US 1999-325480	A1 19990603
			US 2000-478479	A3 20000106


OTHER SOURCE(S):

MARPAT 129:67702


GI




I



II



III



IV


AB The title compds. [I; G = II, III (n = 0, 1; Y = NR₃R₄, C1-6 alkyl, (un)substituted aralkyl; X = N when Y = (un)substituted C1-6 alkyl, aralkyl, and X = CH when Y = NR₃R₄; q = 0-2; m = 0-2; R₃, R₄ = C1-6 alkyl, tetrahydronaphthalene and aralkyl; NR₃R₄ = piperazino, pyrrolidino, etc.)] and their salts, which exhibit activity as nitric oxide synthase (NOS) inhibitors and as such useful in the treatment and prevention of central nervous system and other disorders, were prepared. Thus, e.g., the detailed 7-step synthesis of the title compound IV is described. Of 100 compds. I that were tested, all exhibited an IC₅₀ of < 10 μM for inhibition of either inducible or neuronal NOS.

IT 208837-31-4P 208837-33-6P 208837-35-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-phenylpyridyl-2-amines as NOS inhibitors)


RN 208837-31-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 208837-33-6 CAPLUS


CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 208837-35-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 208837-80-3P 208837-81-4P 208837-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent).
(preparation of 6-phenylpyridyl-2-amines as NOS inhibitors)


RN 208837-80-3 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 208837-81-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 208837-82-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:178911 CAPLUS

DOCUMENT NUMBER: 112:178911

TITLE: Condensation of 4-phenyl-3,5-bis(ethoxycarbonyl)cyclopentane-1,2-dione with primary amines

AUTHOR(S): Afsah, E. M.; Osman, A. I.; Sofan, M.

CORPORATE SOURCE: Fac. Sci., Mansoura Univ., Mansoura, Egypt

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1989),
331(3), 461-5

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 112:178911

GI

DOCUMENT TYPE:
LANGUAGE:
GI

CODEN: YHHPAL; ISSN: 0513-4870
Journal
Chinese




AB 3-Azabicyclo[3.3.1]nonanes, 3-azabicyclo[3.2.1]octanes, and 8-azabicyclo[3.2.1]octanes (.apprx.35 compds.) were prepared. Most of the compds. had strong analgesic activity; I was 2000 times as potent as morphine.

IT 83507-31-7P

RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(formation and reactions of)

RN 83507-31-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-methoxyphenyl)-3-(2-phenylethyl)-
(9CI) (CA INDEX NAME)




IT 83507-59-9P 83507-60-2P 83507-61-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of)


RN 83507-59-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-methoxy-8-(3-methoxyphenyl)-3-(2-phenylethyl)-
, hydrochloride, syn- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl




II



III



IV



V


AB Condensation of the title compound I with primary aromatic amines gave the dianilides, which cyclized to cyclopentadiquinolines II (R = H, Me). Treatment of I with o-phenylenediamine, 2,3-diaminopyridine, or o-aminophenol gave cyclopentabisbenzodiazepine III (X = CH, X1 = NH) and -bispyridodiazepine III (X = N, X1 = NH) or -bisbenzoxazepine III (X = CH, X1 = O) resp. Pechmann reaction of I with m-cresol gave the bisbenzopyran IV. Mannich reaction of I with benzylamine afforded the 3-azabicyclo[3.2.1]octane V.

IT 126517-81-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 126517-81-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octane-1,5-dicarboxylic acid, 6,7-dioxo-8-phenyl-3-(phenylmethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 12. CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1982:582185 CAPLUS

DOCUMENT NUMBER: 97:182185

TITLE: Synthesis and analgesic activity of azabicycloalkanes derivatives


AUTHOR(S): Zhou, Dehe; Fang, Sunan; Ge, Banglun; Li, Qingzhen; Li, Zhiyi; Dai, Qiyuan; Wu, Ruiqin; Wu, Yizhi; Huang, Zhongming; Chen, Xinjian

CORPORATE SOURCE: Shanghai Inst. Mater. Med., Acad. Sin., Shanghai, Peop. Rep. China

SOURCE: Yaoxue Xuebao (1982), 17(7), 503-9

RN 83507-60-2 CAPLUS
CN Phenol, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]-, hydrochloride, syn- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 83507-61-3 CAPLUS
CN Benzenepropanoic acid, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl ester, hydrochloride, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:509115 CAPLUS
DOCUMENT NUMBER: 89:109115
TITLE: Bridged geminal diphenylpiperidines
INVENTOR(S): Eistetter, Klaus; Menge, Heinz Guenter
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 44 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2749584	A1	19780518	DE 1977-2749584	19771105
PRIORITY APPLN. INFO.:			LU 1976-76173	A 19761111

GI For diagram(s), see printed CA Issue.

AB The bridged piperidine derivs. I (X = CH₂, X₁ = CPh₂ optionally substituted by halogen or alkyl; X = (un)substituted CPh₂, X₁ = CH₂; X₂ = bond, NR₁; R = R₁ = H, alkyl, aralkyl; m + n = 1-9] and their salts and N-oxides were prepared Thus, II (R₂ = OH) was stirred with C₆H₆ and AlCl₃


at 40° to give II (R2 = Ph). I are useful for treatment of disturbances of the central nervous system, e.g. Parkinson's disease (no data).

IT 67171-16-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(Friedel-Carfts reactions of, with benzene)

RN 67171-16-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl- (9CI) (CA INDEX NAME)




IT 67171-15-7P 67171-17-9P 67171-29-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 67171-15-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8,8-diphenyl- (9CI) (CA INDEX NAME)



RN 67171-17-9 CAPLUS


CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8,8-diphenyl-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 67171-29-3 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-chloro-3-methyl-8-phenyl-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:64884 CAPLUS

DOCUMENT NUMBER: 66:64884

TITLE: Fragmentation reaction of azabicyclic compounds

AUTHOR(S): Oida, Sadao; Kurabayashi, Masaaki; Ohki, Eiji

CORPORATE SOURCE: Sankyo Co., Ltd., Tokyo, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1966), 14(12), 1418-24

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB A mixture of 1.45 g. 3-methyl-9 β -hydroxy-9 α -phenyl-3-azabicyclo[3.3.1]nonane (I), 30 ml. dry EtOH, and 3 ml. concentrated H₂SO₄ refluxed 4 hrs. gave 1.55 g. 3-methyl-9 β -ethoxy-9 α -phenyl-3-azabicyclo[3.3.1]nonane (II), b₃ 150-60° (bath temperature), purified as the picrate, decomposed at 200°. The corresponding 9 α -hydroxy compound (III) also gave II on refluxing with alc. H₂SO₄. In each case a minor amount of another product, possibly the 9 α -ethoxy epimer, was obtained. Refluxing III with methanolic H₂SO₄ or with propanolic H₂SO₄ gave the corresponding Me ether [leaflets, m. 73-4.5° (MeOH)] and Pr ether [oil; citrate, decomposed at 148°], resp.

3-Methyl-3-azabicyclo[3.2.1]octan-8-one (3 g.) in 20 ml. dry tetrahydrofuran (THF) added slowly with stirring to a Grignard solution prepared by refluxing 4.1 g. PhBr, 0.61 g. Mg turnings, and 20 ml. dry Et₂O, the mixture stirred 3 hrs. at room temperature, and a saturated NH₄Cl solution added to the cooled mixture gave 2.51 g. 3-methyl-8 β -hydroxy-8 α -phenyl-3-azabicyclo[3.2.1]octane (IV), m. 130-1°. A mixture of 500 mg. IV and 5 ml. (EtCO)₂O heated 3 hrs. at 160-5° gave 533 mg. IVa, b_{0.5} 150° (bath temperature). A mixture of 515 mg. I and 5 ml. (EtCO)₂O heated 4 hrs. at 160-70° gave 49 mg. V, b₁ 130° (bath temperature), isolated as the picrate, yellow leaflets, m. 137-9°, and 335 mg. VI, b_{0.05} 180° (bath temperature). A solution of 0.44 g. VI in 10 ml. Et₂O 4 hrs. with excess MeI gave 0.74 g. V methiodide, leaflets, m. 198-9° (MeOH-Et₂O). III treated similarly with (EtCO)₂O also gave V and VI. VI (294 mg.) in 3 ml. cold dry tetrahydrofuran (THF) treated portionwise with 50 mg. LiAlH₄, and the mixture then refluxed 3 hrs. gave 253 mg. pale yellow liquid, which, on refluxing 2.5 hrs. in 5 ml. Et₂O with excess MeI gave 399 mg. VII, m. 163-5° (Et₂O-MeOH). Hofmann degradation of V methiodide gave NMe₃ [isolated as the picrate (70 mg.)] and 0.12 g. VIII, b₂₀ 160° (bath temperature). VII similarly gave 43 mg. NMe₂Pr picrate and 93 mg. VIII. A solution of 310 mg. VI in 25 ml. 1:1:1 MeOH-H₂O-concentrated HCl refluxed 3 hrs. gave 30 mg. IX, m. 102-3° (hexane-EtOAc). LiAlH₄ (30 mg.) added in small portions to a stirred solution of 191 mg. IX in 2 ml. dry THF, and the mixture refluxed 6 hrs. gave 128 mg. X, b_{0.05} 150° (bath temperature). X with MeI gave 77% of the methiodide (XI), decomposed at 150° (MeOH-Et₂O). Hofmann degradation of XI with Ag₂O gave 120 mg. 5-hexenyl phenyl ketone, b₇ 180-90°

(bath temperature); 2,4-dinitrophenylhydrazone m. 142-3° (EtOH). A solution of 2.5 g. I (or III), 3 g. HOAc, and 18 g. NaOAc in 200 ml. H2O heated at 160-70° in an autoclave 3 hrs. gave 57 mg. of an amine (C12H21N), m. 47.5-8.5° [picrate (C21H24O4N4), decomposed at 190°], and 404 mg. V. These facts illustrate the tendency of the skeleton of 9-phenylazabicyclo[3.3.1]nonane to yield a carbonium ion. The structures are confirmed by ir, uv, and N.M.R. spectra.


IT 15466-28-1P 15466-29-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 15466-28-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 15466-29-2 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8 α -phenyl-, propionate
(ester) (8CI) (CA INDEX NAME)

Relative stereochemistry.



=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

61.78	228.93
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-9.00	-9.00
-------	-------

FILE 'STNGUIDE' ENTERED AT 09:40:08 ON 06 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 1, 2006 (20061201/UP).

=> d his

(FILE 'HOME' ENTERED AT 09:38:45 ON 06 DEC 2006)

FILE 'REGISTRY' ENTERED AT 09:39:01 ON 06 DEC 2006

L1 STRUCTURE UPLOADED

L2 13 S L1
L3 204 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:39:38 ON 06 DEC 2006
L4 12 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 09:40:08 ON 06 DEC 2006

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.30	229.23
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-9.00

STN INTERNATIONAL LOGOFF AT 09:43:01 ON 06 DEC 2006